- Home
- LBPH vs JBGS Comparison
LBPH vs JBGS Comparison
Compare LBPH & JBGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LBPH
- JBGS
- Stock Information
- Founded
- LBPH 2020
- JBGS 2016
- Country
- LBPH United States
- JBGS United States
- Employees
- LBPH N/A
- JBGS N/A
- Industry
- LBPH Biotechnology: Pharmaceutical Preparations
- JBGS Real Estate Investment Trusts
- Sector
- LBPH Health Care
- JBGS Real Estate
- Exchange
- LBPH Nasdaq
- JBGS Nasdaq
- Market Cap
- LBPH 1.4B
- JBGS 1.4B
- IPO Year
- LBPH 2021
- JBGS 2017
- Fundamental
- Price
- LBPH $59.81
- JBGS $15.60
- Analyst Decision
- LBPH Buy
- JBGS Sell
- Analyst Count
- LBPH 8
- JBGS 1
- Target Price
- LBPH $52.29
- JBGS $17.00
- AVG Volume (30 Days)
- LBPH 834.8K
- JBGS 528.2K
- Earning Date
- LBPH 11-07-2024
- JBGS 10-29-2024
- Dividend Yield
- LBPH N/A
- JBGS 4.45%
- EPS Growth
- LBPH N/A
- JBGS N/A
- EPS
- LBPH N/A
- JBGS N/A
- Revenue
- LBPH N/A
- JBGS $567,034,000.00
- Revenue This Year
- LBPH N/A
- JBGS N/A
- Revenue Next Year
- LBPH N/A
- JBGS N/A
- P/E Ratio
- LBPH N/A
- JBGS N/A
- Revenue Growth
- LBPH N/A
- JBGS N/A
- 52 Week Low
- LBPH $3.60
- JBGS $13.04
- 52 Week High
- LBPH $59.95
- JBGS $18.86
- Technical
- Relative Strength Index (RSI)
- LBPH 78.81
- JBGS 36.10
- Support Level
- LBPH $59.47
- JBGS $14.78
- Resistance Level
- LBPH $59.85
- JBGS $17.58
- Average True Range (ATR)
- LBPH 0.20
- JBGS 0.54
- MACD
- LBPH -0.84
- JBGS -0.13
- Stochastic Oscillator
- LBPH 86.36
- JBGS 26.20
About LBPH Longboard Pharmaceuticals Inc.
Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies.
About JBGS JBG SMITH Properties
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in and develops real estate assets concentrated in urban infill submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to the legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily and third-party asset management and real estate services. The company generates majority of its revenue from Commercial segment.